A detailed history of Meeder Asset Management Inc transactions in Insmed Inc stock. As of the latest transaction made, Meeder Asset Management Inc holds 55 shares of INSM stock, worth $4,061. This represents 0.0% of its overall portfolio holdings.

Number of Shares
55
Previous 47 17.02%
Holding current value
$4,061
Previous $3,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$62.0 - $79.01 $496 - $632
8 Added 17.02%
55 $4,000
Q2 2024

Aug 08, 2024

BUY
$22.0 - $69.71 $1,034 - $3,276
47 New
47 $3,000
Q3 2021

Nov 08, 2021

SELL
$22.46 - $29.47 $39,057 - $51,248
-1,739 Closed
0 $0
Q2 2021

Aug 09, 2021

SELL
$24.17 - $36.01 $15,227 - $22,686
-630 Reduced 26.59%
1,739 $49,000
Q1 2021

Apr 28, 2021

BUY
$32.28 - $44.3 $76,471 - $104,946
2,369 New
2,369 $83,000
Q4 2020

Feb 09, 2021

SELL
$31.45 - $40.54 $87,368 - $112,620
-2,778 Closed
0 $0
Q3 2020

Nov 02, 2020

BUY
$26.0 - $34.5 $46,566 - $61,789
1,791 Added 181.46%
2,778 $90,000
Q2 2020

Aug 11, 2020

BUY
$14.11 - $29.42 $4,853 - $10,120
344 Added 53.5%
987 $27,000
Q1 2020

May 15, 2020

BUY
$13.63 - $33.98 $8,764 - $21,849
643 New
643 $10,000
Q3 2019

Oct 17, 2019

SELL
$15.49 - $25.78 $851 - $1,417
-55 Closed
0 $0
Q2 2019

Aug 05, 2019

BUY
$23.0 - $32.19 $207 - $289
9 Added 19.57%
55 $1,000
Q1 2019

Apr 16, 2019

SELL
$13.91 - $31.15 $1,975 - $4,423
-142 Reduced 75.53%
46 $1,000
Q4 2018

Jan 17, 2019

BUY
$11.6 - $18.7 $2,180 - $3,515
188 New
188 $2,000
Q1 2018

May 03, 2018

SELL
$21.69 - $32.99 $3,817 - $5,806
-176 Closed
0 $0
Q4 2017

Feb 02, 2018

SELL
$26.43 - $31.78 $2,114 - $2,542
-80 Reduced 31.25%
176 $5,000
Q3 2017

Oct 20, 2017

BUY
$11.61 - $31.21 $2,972 - $7,989
256
256 $8,000

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $10B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Meeder Asset Management Inc Portfolio

Follow Meeder Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.